• Biosimilars, Biobetters, Or Both?: Report Highlights Manufacturing Considerations
    Biosimilars, Biobetters, Or Both?: Report Highlights Manufacturing Considerations

    I sat down with Kate Hammeke, VP of Industry Standard Research to discuss the biggest surprises or takeaways from this year’s report about the industry’s biologics and biosimilars manufacturing goals. But the conversation also evolved to some of the larger trends Hammeke expects to see impacting the biosimilar players in the future.

Samsung Bioepis: Applying The "Hunger" For Biosimilars To Novel Drugs

Since last year's feature article celebrating Samsung Bioepis' fifth anniversary, the company has seen a number of approvals and launches and has established a novel biologics development partnership. As such, I jumped on the opportunity to learn more about the company's ongoing efforts to realize a lower COGS, speed production, and manage risk in biosimilar and biologics development.

New U.S And Canadian Facilities Boosting Biologics Capacity

Biopharma executives have warned they need more biologics development and manufacturing capacities, particularly in North America. They haven’t been howling at the moon. Four announcements – within two days of each other – offer a sign of relief. And Amgen has provided Outsourced Pharma with its first public estimate of costs for one of those facilities.

Why Biosimilars Won’t Be “A Stake In The Heart Of Innovation”

There has not been much discussion about how biosimilars contribute to or will impact innovation — outside of helping the healthcare system afford costly novel therapies. I found my interest in this question sparked upon reading a recent headline, "Biosimilars: The Cure for Sky-High Drug Prices Or A Stake In The Heart Of Innovation?"

2018 Outlook: Biosimilar Trends To Watch

Last week, I published the first installment of a three-part roundtable discussion highlighting which 2017 trends/occurrences were most notable to the members of Biosimilar Development’s editorial advisory board. In addition to discussing 2017’s impact on the future of the industry, these experts also shared their thoughts on what to expect in 2018.

More From Our Editors


  • Combination Products Vs. Combination Therapies: What's The Difference?

    As technology advances and experimentation with existing approved entities broadens, the use of “combinations” will continue, and the proper use of them will depend on regulatory professionals reminding development teams of the differences as data becomes available.

  • Nitroso Impurities In Valsartan: How Did We Miss Them?

    The EMA and the FDA reported a major issue regarding the detection of a genotoxic impurity, NDMA (N-nitrosodimethylamine), and subsequently NDEA (N-nitrosodiethylamine), in lots of valsartan, an API used to manufacture generic angiotensin receptor blockers. The API at issue was supplied by two Chinese companies and was later discovered in API manufactured by an Indian manufacturer.

More From Guest Contributors


More Bioprocessing White Papers


More Industry Insights


Pharmacy Benefit Compliance Congress November 13 - 14, 2018
Scottsdale, AZ
GDPR Forum for Life Sciences November 13, 2018
7th Annual Pharmacy Benefit Compliance Congress November 13 - 14, 2018
Scottsdale, AZ
GDPR Forum November 13, 2018
Complimentary Bioprocess Workshop November 13, 2018
Burlingame, CA
More Industry Events


Clinical Study Requirements – Understanding Differences Between the US and EU November 15 - 15, 2018
1pm-2:30pm EST, Online Training
Blockchain Technology for the Life Sciences: A Comprehensive Primer November 27 - 27, 2018
1pm-2:30pm EST, Online Training
Adverse Event Reporting: Avoiding Common Pitfalls December 11 - 11, 2018
1pm-2:30pm EST, Online Training
More Upcoming Courses